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Abstract
Purpose: Pediatric patients require special attention from pediatric pharmacists. This is particularly true for
pediatric patients with chronic kidney disease (CKD) as the number of their medications and the complexity of their
treatment increase with disease progression. However, there is paucity of information describing pediatric
cognitive pharmacy services in this setting. The objective of this study is to identify the potential roles of a clinical
pharmacist as a provider in a pediatric nephrology and hypertension clinic. Methods: Pediatric patients (≤18 years
of age) who chronically took at least one medication were consecutively enrolled at the University of North Carolina
(UNC) Pediatric Nephrology and Hypertension Clinic from 1 August 2007 to 15 April 2008. Demographic informa-
tion and the interventions performed during the clinic visit by a clinical pharmacist were examined. Results: Three
hundred and seventy-four visits made in 283 participants were evaluated. The mean (SD) number of cognitive phar-
macy interventions per patient was 2.3 (1.0) on the first visit, with medication counseling and verification of current
medications comprising the most common activity (85%). The mean (SD) number of medications per patient was
5.7 (4.8) and of medications counseled per visit was 4.0 (3.4). Medication adherence was investigated in 141 (38%)
visits. Pretransplant education on medications was performed in 3% of the patients. Discrepancies of medications
were discovered in 12 of the 374 visits. Conclusion: Pediatric cognitive pharmacy services to patients at the UNC
pediatric nephrology clinic were feasible, which improved the quality of services and promoted better outcomes for
these complex patients.
Keywords: cognitive pharmacy service, pediatric, chronic kidney disease, hypertension, medication adherence, 
medication discrepancy, medication counseling, kidney transplantation, electronic health record, electronic medical 
profile, electronic medical record
INTRODUCTION
Children require special attention from pediatric phar-
macists. This is particularly true for pediatric patients
with chronic kidney disease (CKD) as the number of
medications and the complexity of their treatment plan
increase with disease progression. The pharmacokinet-
ics and pharmacodynamics of medications in the
pediatric population differ from those in the adult
population.1 Even within pediatrics, neonates and
older children have different rates of absorption,
metabolism, and elimination. All these factors deal with
the pharmacokinetic disposition of medications.
Because of these complexities and challenges, it is vital
for pediatric pharmacists to be part of the medical team
given their expertise in these areas of pharmacotherapy.
No literature, however, exists to document the impor-
tance of clinical pharmacy services at a pediatric medi-
cal clinic.
In recent decades, pharmacists’ roles have expan-
ded from the mere dispensing of medications to a
clinical role managing patients’ medication therapy.
This contemporary approach by pharmacists is known
as cognitive pharmacy service.2 Cognitive pharmacy
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services are defined as services provided by pharmacists
related to the management of the effectiveness and
appropriateness of patients’ therapeutic regimens.2
These services can be divided into two major catego-
ries: pharmaceutical care and disease-state manage-
ment. Pharmaceutical care consists of evaluation of
patients’ pharma- cotherapy, minimization and detec-
tion of adverse medication events and drug interac-
tions, provision of patient education on the information
pertaining to medication indications and potential
adverse effects with special instructions on medication
administration, monitoring patients’ progress on thera-
pies, and aiding in the transition of patients’ care
between inpatient and outpatient settings.2 Disease-
state management, in this context, is defined as the
continuous services provided by a clinician (e.g., clini-
cal pharmacist) to manage the well-being of the
patients over the course of a disease.3 These services
consist of developing and implementing efficacious and
cost-effective treatment for the disease states such as
asthma, diabetes, and hypertension. These services
require a multidisciplinary approach, including physi-
cians, nurses, and pharmacists.3
Cognitive pharmacy services in adult clinical settings
have been shown to help patients control hyperten-
sion,4 minimize the amount of sub- or supratherapeutic
drug concentrations,5 and achieve serum glucose con-
trol.6 Pharmacists’ interventions also decrease the
number of adverse drug events in the outpatient
setting7–10 and help identify medication discrepancies,
reported to occur in up to 60% of adult patients on
hemodialysis.11 Pharmacists can also provide medica-
tion counseling and identify potential drug interac-
tions.7–10 In the management of patients with CKD, a
clinical pharmacist can also provide blood pressure,
anemia, and hyperlipidemia management and screen-
ing for proteinuria.12 At a community health clinic con-
sisting of high-risk adult patients with CKD, clinical
pharmacists were able to provide various therapeutic
recommendations including the adjustment of antihy-
pertensive medications, discontinuation of nonsteroidal
anti-inflammatory agents, and addition of renoprotec-
tive medications.13
There is paucity of information describing pediatric
cognitive pharmacy services. Our study describes these
activities performed at the University of North Carolina
Kidney Center (UNCKC) Pediatric Nephrology and
Hypertension Clinic over an 8-month period. Most of
these services were provided in the outpatient setting as
part of the pediatric pharmacotherapy residency at the
UNC Hospitals, complementing the dedicated full-
time pediatric pharmacy services in the inpatient set-
ting. The objective of this descriptive study was to
identify the potential roles of a clinical pharmacist as a
provider in a pediatric nephrology and hypertension
clinic. To our knowledge, our study is the first study
documenting cognitive pharmacy services at this pedi-
atric setting.
MATERIALS AND METHODS
New or returning pediatric patients (≤18 years of age)
who chronically took at least one medication were
consecutively enrolled at the UNCKC Pediatric Neph-
rology and Hypertension Clinic, from 1 August 2007 to
15 April 2008. The UNCKC Pediatric Nephrology and
Hypertension Clinic is a referral clinic for children and
adolescents with CKD stages 1–6 and hypertension
from Central and Eastern North Carolina. This study
was approved by the Committee for Human Research
Protection of the Institutional Review Board at UNC at
Chapel Hill with waiver of informed consent.
Although most pediatric cognitive pharmacy services
occurred during scheduled visits with the pediatric
nephrologists in the outpatient setting, they comple-
mented the inpatient pharmacy services provided by a
dedicated pediatric clinical pharmacist.
The clinical pharmacist also provided counseling
and drug education services to kidney transplant candi-
dates (weekly or monthly) concomitant to their clinic
visits with the nephrologists. Once all cognitive phar-
macy services were completed, the pharmacist would
discuss treatment recommendations and pharmaceuti-
cal issues with the physician before his/her medical
evaluation. The physician would wait for the pharma-
cist to finish his encounter with the patient before going
into the room to evaluate the patient. If medication
changes were made during the visit, the pharmacist
would see the patient again at the end to provide
further counseling.
The pharmacist’s clinical activities were documented
in the patients’ electronic health record after each visit
in a concise dedicated note. This note captured (1) the
number of medications that the patients were on at the
beginning of the visit; (2) the number of medications
updated in the patients’ electronic profile; (3) medications
for which patients received counseling; and (4) other
cognitive pharmacy services that were provided during
the clinic visits. These cognitive services were not
charged to the patients’ medical bill.
Demographic and medical information were col-
lected. Patients were classified as having “glomerular,”
“nonglomerular” disease, and “hypertension only.”
Two secondary diagnoses (hypertension and anemia)
were identified because these were the second and third
most common clinical conditions following CKD. The
interventions performed during the clinic visit by the
clinical pharmacist were classified as (1) counseling
and/or verification of understanding on current medi-
cations; (2) adherence assessment; (3) conveying
patients’ concern/issues regarding their medications to
physicians; (4) provision of information to patients/
parents on medications that were not prescribed by
their nephrologists; (5) medication dosing/monitoring
recommendations; (6) provision of drug information
resource; (7) identification of medication discrepancy;
(8) medication education for kidney transplant candidate;
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(9) new medication counseling; and (10) updating drug
allergies. Finally, customized letters warning against
pregnancy were handed to females of child-bearing age
if they were on an angiotensin-converting enzyme
inhibitor or angiotensin receptor antagonist.
If the patients did not bring their medications to the
clinic visit and/or if the clinical pharmacist had any sus-
picion that the patients were not adherent (e.g., sub-
therapeutic drug concentration; discrepancy in reports
of how they took their medications), the clinical
pharmacist would call the patient’s pharmacy to obtain
the refill rate. We determined a patient’s presumed
adherence rate by a review of medical records and by
contacting their pharmacy to assess medication refill
frequency using a published nonadherence definition of
less than 80% adherence to medication regimen.14
Statistical Analysis
All analyses were done with SAS™ version 9.1.3 (SAS
Institute, Cary, NC, USA). Simple descriptive statistics
were computed for categorical variables, such as fre-
quencies of interventions and demographic variables.
Means of continuous variables by race, sex, and diag-
nosis were compared by analysis of variance (ANOVA)
and Turkey’s multiple comparisons of means. Distribu-
tion of categorical variables by race, sex, or diagnosis
was compared by chi-square tests. An a-value of less
than 0.05 was considered as significant.
RESULTS
Pediatric cognitive pharmacy services were adminis-
tered to 283 study participants in 374 clinic visits.
Table 1 depicts the baseline characteristics of the study
participants. The mean (SD) age was 10.3 (5.6) years
and the mean (SD) age at diagnosis was 8.1 (5.7)
years. The participants’ diagnosis distribution was
“nonglomerular diseases” (69.2%), “glomerular dis-
eases” (18.4%), and “hypertension only” (12.4%).
Of the 283 participants, 32 (11%) had anemia, and
hypertension (primary or secondary) was noted in 111
participants (39%) (see Table 1). More African
Americans had a diagnosis of hypertension compared with
participants of other ethnicities (p = 0.004) (Table 2).
Fewer African Americans had nonglomerular disease
than Caucasians or other ethnicities (p = 0.004), and
more African Americans had glomerular diseases than
both Caucasians and other ethnicities (p = 0.02)
(Table 2). Females had more glomerular disease than
males (p = 0.04).
The duration of pharmacy cognitive services lasted
from 10 to 25 minutes and included interactions
with the patients and/or their parents. The pediatric
clinical pharmacist services included patient educations
on medication indications (both prescribed medica-
tions and over-the-counter medications) and potential
adverse effects with special considerations at the
time of medication administration. Drug interactions,
medication discrepancies, and potential pharmacother-
apy dosing recommendations based on parameters
such as drug levels, patients’ weight and renal function
were also conveyed to the physicians before their visit
with the patient.
If the patients or the parents were perceived to have
inadequate understanding of their medications, the
pediatric clinical pharmacist would provide follow-up
services at subsequent visits until adequate understand-
ing was acquired. This encompassed approximately 5%
of the visits.
Responses to pharmacy-related questions and
dosing questions posed by patients and physicians,
respectively, were given in 28% of the clinic visits.
Pretransplant education on medications was performed
in 3% of the visits. Discrepancies between the medica-
tion history provided by the patient/family and the elec-
tronic medical record were discovered in 12 of the 374
visits (3%). Presumed adherence with medical treat-
ment was investigated in 141 (38%) of the visits and
the rate of nonadherence was around 15%. Table 3
listed the rest of the interventions by category.
The mean (SD) number of cognitive pharmacy
interventions per patient was 2.3 (1.0) on the first
visit, with medication counseling and verification of
current medications comprising the most common
Table 1. Characteristics of patients who received pediatric
cognitive pharmacy services at the UNCKC Pediatric
Nephrology and Hypertension Clinic (n = 283).
Patient characteristics Values
Age in years, mean (SD)
Current age 10.3 (5.6)






African American 109 (39)
Other 53 (18)
Primary diagnosis, n (%)
Glomerular disease 52 (18.4)
Nonglomerular diseasea 196 (69.2)
Hypertension only 35 (12.4)
Secondary diagnosis, n (%)
Hypertensionb 76 (27)
Anemia 32 (11)
Stages of chronic kidney diseasec, n (%)
Chronic kidney disease stages 1–4 22 (8)
Kidney transplantation 25 (9)
Hemodialysis 4 (1)
Peritoneal dialysis 4 (1)
Medications, mean (SD)
Number of medications 4.4 (4.2)
Notes: University of North Carolina Kidney Center (UNCKC).
aCongenital urinary tract anomalies, hereditary, and tubulointer-
stitial conditions.
bDid not include “primary hypertension only.”
cDefinitions according to the KDOQI guidelines.25
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activity (85%) (Table 3). The mean (SD) number of
medications prescribed to each patient was 5.7 (4.8),
and the mean (SD) number of medications counseled
per visit was 4.0 (3.4) (see Table 4). Patients
with glomerular disease had significantly more medi-
cations than those with nonglomerular disease or
hypertension only (p = 0.002), and patients dependent
on hemodialysis or kidney transplantation had
significantly more medications than patients with
CKD stages 1–4 (p < 0.05). Other significant findings
related to the number of medications by secondary
diagnoses are reported in Table 5. There was not a
significant difference in the number of medications
per patient by sex or ethnicity (p = 0.8 and p = 0.2,
respectively) (data not shown).
On average, two medication updates in the patient’s
electronic medical profile were made during each visit
(Table 4). Medications were updated in 51% of initial vis-
its, which followed by 47% and 54% during their second
and third visits, respectively (data not shown). Table 6
showed common specific interventions that were made to
the cohort.
Table 2. Distribution of diagnoses by ethnicities.
Caucasians 
n = 121 (%)
African 
American 
n = 109 (%)
Other 
ethnicities 




Glomerular disease 16 (13) 29 (27) 7 (13) 0.02
Nonglomerular disease 93 (77) 63 (58) 40 (75) 0.004
Hypertension only 12 (10) 17 (16) 6 (11) 0.4
Anemia 9 (7) 18 (17) 5 (9) 0.08
Hypertension (primary + secondary 
diagnosis)
35 (29) 56 (51) 20 (38) 0.004
Table 3. Cognitive pharmacy services by pediatric clinical
pharmacist (n = 374 visits).
Services Count %
Counseling and/or verification of 
understanding on current medications
316 85
Adherence assessment 141 38
Conveying patients’ concerns/issues regarding 
their medications to physicians
120 32
Provision of information to patients/parents 






Provision of drug information resource 21 6
Identification of medication discrepancy 12 3
Medication education for kidney transplant 
candidates
10 3
New medication counseling 10 3
Updating drug allergies 3 1












Visit 1 (n = 283) 4.4 (4.2) 1.1 (1.9) 3.6 (3.3)
Visit 2 (n = 58) 6.5 (4.8) 1.0 (1.4) 4.0 (4.1)
Visit 3 (n = 13) 9.5 (6.5) 1.0 (1.0) 3.7 (3.8)
Visit 4 (n = 7) 11.6 (5.6) 2.3 (2.5) 5.7 (5.3)
Visit 5 (n = 5) 8.4 (6.2) 0.6 (1.3) 0.8 (1.1)
Visit 6 (n = 2)a 14.5 (2.1) 2.5 (2.1) 8.5 (10.6)
Total (n = 368) 5.7 (4.8) 2.2 (1.8) 4.0 (3.4)
Notes: Each patient can have multiple visits (up to 12 visits in
this cohort).
aAdditional visits with n = 1 were not included in this summary
(up to 6 visits are presented here because visits 7–12 were mainly
made by few repeated patients).







Primary diagnosis (n = 283) 0.002
Glomerular disease 6.2 (4.9)b
Nonglomerular disease 3.9 (3.9)
Hypertension only 3.9 (4.4)
Stages of chronic kidney 
diseases (n = 55)
0.01
Chronic kidney disease 
stages 1–4
6.2 (4.0)
Peritoneal dialysis 8.5 (1.9)
Hemodialysis 11.3 (2.1)
Kidney transplantation 9.7 (4.2)c
Secondary diagnosis (n = 283) <0.0001
Anemia and hypertension 10.0 (3.9)d
Anemia only 7.1 (1.5)e
Hypertension only 6.2 (4.5)
None 3.1 (3.5)
Notes: aThis statistical test does not directly compare groups
to each other (e.g., glomerular disease vs. hypertension only).
It answers the question “are all groups equal?” The followings
are different tests that look at comparisons between the
subgroups.
bGlomerular disease is higher than nonglomerular disease and
hypertension only, p < 0.05.
cKidney transplantation is higher than CKD stages 1–4, p < 0.05.
dAnemia and hypertension are higher than hypertension only or
none, p < 0.05.
eAnemia is higher than none, p < 0.05.
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DISCUSSION
A multidisciplinary approach is vital in the manage-
ment of clinical conditions such as renal diseases and
hypertension in the pediatric population. Our study
describes different interventions that a pediatric clin-
ical pharmacist can provide at a pediatric nephrology
and hypertension clinic and how such services may
improve patients’ clinical outcomes. To our knowl-
edge, this is also the first study that documents the
burden of medications in the pediatric nephrology
setting.
Pediatric prescriptions are often more difficult for
patients and their parents to comprehend due to the
various available formulations and concentrations.15
One example is epoetin alfa, which is commercially
available in 2000, 3000, 4000, 10,000, 20,000, and
40,000 U/mL. As proven in the adult literature,
patients may not be adherent if they do not have a
good understanding of the indications and the direc-
tions of the medications.16 It is established that pedi-
atric patients are less adherent when there is a lack of
parenteral supervision and appropriate drug formula-
tions.17 Nonadherence with medications is detrimen-
tal and may lead to short- or long-term medical
consequences such as transplant loss18 and inappro-
priate adjustments in medication dosages leading to
subsequent toxicity, such as with tacrolimus and
cyclosporine.17 With the shortage of pediatric neph-
rologists and the increasing number of referrals to
this subspecialty practice, pediatric pharmacists will
have ample opportunities to provide cognitive phar-
macy services to CKD patients in the outpatient set-
ting. These services, however, have not been
described in pediatric nephrology clinics.
Disease-state management consists of active partici-
pation by pharmacists collaborating with other health
care providers in the designing and implementing
of patients’ pharmacotherapy.3 These disease states
include but are not limited to anemia,20 hypertension,4
and renal osteodystrophy.21
The most frequent cognitive pharmacy service
provided in our study was direct counseling of patients
and families regarding the medication regimen. During
the time of this study, it became evident that often a
family’s understanding of medication indications and
side effects was a major challenge. This in part may be
related to the literacy level of our patient population.22
The lack of understanding of the medications can also
be related to the difficulty in interpreting medication
labels.23 Because of the below-average literacy level of
our patient population, the clinical pharmacist made a
concerted effort to counsel patients using metaphors.
For example, if the patient takes tacrolimus, the phar-
macist would describe it as the “protector” of the kid-
ney. In addition to verbal counseling, printed literature
was also provided as long as the literacy level was
acceptable. Medication discrepancies, both in dispens-
ing and prescribing, have been a major issue in the
medical arena, especially in the ambulatory care set-
ting.11,24 Discrepancies in our setting were identified
by reconciling patients’ medications with the physi-
cians’ last clinic note or discharge summary. These
findings are especially important in instances where
medications are potentially harmful. In our study, med-
ication discrepancies were discovered in only 3% of the
clinic visits, compared with 60% in one observational
study at a hemodialysis center.11 The difference in our
discrepancy rate is likely a reflection of several services
already provided at the UNC Hospital System such as:
(a) dedicated inpatient pediatric pharmacy services
(including daily inpatient rounds with the pediatric
pharmacists at the bedside); (b) medication profiles
updated and consolidated at the time of discharge by
our medication system within an electronic health
record; and (c) the triage nurses in the outpatient clinic
who update medication and drug allergy profiles. The
combination of dedicated staff and integrated inpatient
and outpatient electronic medical record system is vital
in preventing medication-related problems in patients
with end-stage renal disease.24
To have a pediatric pharmacist available at the clinic
made it convenient for the patients to ask various med-
ication-related questions, enhancing the patients’ and
their parents’ knowledge. During the clinic visit, the
patients or the parents would also tell the pharmacist
problems or side effects that they might encounter in
obtaining and taking the medications, respectively. The
clinical pharmacist would in turn convey such informa-
tion to the physicians and work as a team to devise a
solution to the problem.
The clinical pharmacist is also a good resource to the
physicians in terms of medication dosage recommenda-
tions and provision of evidence-based literature on the use
of certain medications in the pediatric population. The
frequency of these activities seems low in our cohort, but
this observation is also a reflection of the dedicated
Table 6. Common specific interventions related to pediatric
nephrology patients.
1. Adjustment of calcineurin inhibitor dose based on serum 
concentration
2. Adjustment of erythropoiesis-stimulating agent dose based 
on hemoglobin levels
3. Adjustment of anti-hypertensive medications based on blood 
pressure measurement
4. Adjustment of vitamin D, Ca, and P-binders based on serum 
levels
5. Recommendation of iron therapy
6. Recommendation of different formulations of K and P 
supplements
7. Recommendation of pharmacotherapy for insomnia
8. Counseling on immunosuppressants
9. Provision of letters warning about ACEI or ARB fetopathy
10. Verification of erythropoiesis-stimulating dose and 
concentrations
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inpatient pediatric pharmacy services and education at
our institution, an example of great continuum of care.
One of the most involved and time-consuming tasks
that the pediatric clinical pharmacist performed was to
prepare kidney transplant candidates for their future
medication regimen. This process is especially chal-
lenging if the patients or their parents have lower
literacy skills. In the case of an English-speaking but
illiterate mother of a kidney transplant candidate,
weekly meetings with the pharmacist and the provision
of pictorial diagrams of the medications accomplished
this task. Because of these interventions, this child was
finally activated in the transplant list, received a trans-
plant, and has been rejection-free.
Medication adherence is vital in patients with
hypertension and renal diseases, especially in those
patients post-transplantation as pointed out by
Ettenger et al.18 The clinical pharmacist was able to
contact the patients’ home pharmacy if he/she deemed
that the patients were not adherent based on their hes-
itation to answer questions or decreased blood levels
of immunosuppressants. Future studies, however,
should be conducted to assess the improvement of
patients’ adherence through the clinical pharmacist’s
cognitive services. The possibility of conducting
pharmacist-only visits to enhance patients’ under-
standing and knowledge of their medication regimens
and aiding in medications management remains to be
explored.
Even though these cognitive services provided by the
clinical pharmacists were free of charge to patients, a
possible cost can be calculated. In our study, 737 cog-
nitive pharmacy interventions were made. If each inter-
vention was for 10 minutes, then 7370 minutes or
about 123 hours of pharmacist-time were consumed.
These pharmacist-hours can potentially be converted
to monetary value based on pharmacoeconomic data,
but this discussion is beyond the scope of this article.
CONCLUSIONS
Pediatric cognitive pharmacy services at the UNCKC
Pediatric Nephrology and Hypertension Clinic pro-
vided a vast amount of clinical interventions designed
to improve patients’ care and their understanding on
their medications, especially in patients undergoing
kidney transplantation. The role that the clinical phar-
macist played at the clinic was valuable as it highlighted
the gaps in patient’s understanding of their medication
profile. The cost-effectiveness of such practice can
potentially be calculated.
Acknowledgments
We thank Melanie Joy, PharmD, associate professor in
the Division of Nephrology and Hypertension at the
UNC at Chapel Hill, for her insightful comments to
this work.
Declaration of interest: The authors report no con-
flicts of interest. The authors alone are responsible for
the content and writing of the paper.
REFERENCES
[1] Skaer TL. Dosing considerations in the pediatric patient. Clin
Ther. 1991;13:526–544.
[2] Hepler CD, Strand LM. Opportunities and responsibili-
ties in pharmaceutical care. Am J Hosp Pharm. 1990;47:
533–543.
[3] Armstrong EP, Sclar DA. Disease management: State of the
art and future directions. Clin Ther. 1999;21:593–609.
[4] Bogden PE, Abbott RD, Williamson P, Onapa JK, Koonz
LM. Comparing standard care with a physician and pharma-
cists team approach for uncontrolled hypertension. J Gen
Intern Med. 1998;13:745–745.
[5] Radley AS, Hall J, Farrow M, Carey PJ. Evaluation of antico-
agulant control in a pharmacist operated anticoagulant clinic.
J Clin Pathol. 1995;48:543–547.
[6] Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran
H. Evaluation of a pharmaceutical care model on diabetes
management. Ann Pharmacother. 1996;30:238–243.
[7] Bond CA, Salinger RJ. Fluphenazine outpatient clinic – phar-
macists role. J Clin Psychiatry. 1979;40:501–503.
[8] Monson R, Bond CA, Schuna A. Role of the clinical pharma-
cist in improving drug therapy. Clinical pharmacists in outpa-
tient therapy. Arch Intern Med. 1981;141:1441–1444.
[9] McKenney JM, Witherspoon JM. The impact of outpatient
hospital pharmacists on patients receiving antihypertensive
and anticoagulant therapy. Hop Pharm. 1985;20:406–415.
[10] Dorevitch A, Aronzon R, Zilberman L. Medication mainte-
nance of chronic schizophrenic outpatients by a psychiatric
clinical pharmacist: 10-year follow-up study. J Clin Pharm
Ther. 1993;18:183–186.
[11] Manley HJ, Drayer DK, McClaran M, Bender W, Muther
RS. Drug record discrepancies in an outpatient electronic
medical record: Frequency, type, and potential impact on
patient care at a hemodialysis center. Pharmacotherapy. 2003;
23:231–239.
[12] Joy MS, DeHart RM, Gilmartin C, et al. Clinical pharma-
cists as multidisciplinary health care providers in the manage-
ment of CKD: A joint opinion by the nephrology and
ambulatory care practice and research networks of the American
College of Clinical Pharmacy. Am J Kidney Dis. 2005; 45:
1105–1118.
[13] Patel HR, Pruchnicki MC, Hall LE. Assessment for chronic
kidney disease services in high-risk patients at community
health clinics. Ann Pharmacother. 2005;39:22–27.
[14] Hilbrands L, Hoitsma A, Koene R. Medication
compliance after renal transplantation. Transplantation 1995;
60:914–920.
[15] Sano PY, Masotti RR, dos Santos AA, Cordeiro JA. Evalua-
tion of the understanding level of pediatric prescriptions.
J Pediatr. (Rio J.) 2002;78:140–145.
[16] Lau HS, Beuning KS, Postma-Lim E, Klein-Beernink L, Boer
A, Porsius AJ. Non compliance in elderly people: Evaluation
of risk factors by longitudinal data analysis. Pharm World Sci.
1996;18:63–68.
[17] Matsui D. Current issues in pediatric medication adherence.
Pediatr Drugs. 2007;9:283–288.
[18] Ettenger RB, Rosenthal JT, Marik JL, et al. Improved cadav-
eric renal transplant outcome in children. Pediatr Nephrol.
1991;5:137–142.
[19] Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL,
Falk RJ. Reengineering clinical operations in a medical prac-
tice to optimize the management of anemia of chronic kidney
disease. Pharmacotherapy. 2007;27:733–744.
Cognitive Pharmacy Services at a Pediatric Nephrology and Hypertension Clinic 25
© 2011 Informa Healthcare USA, Inc.
[20] Zillich AJ, Saseen JJ, Dehart RM, et al. Caring for patients
with chronic kidney disease: A joint opinion of the ambulatory
care and the nephrology practice and research networks of the
American College of Clinical Pharmacy. Pharmacotherapy.
2005;25:123–143.
[21] Belsante M, Burnett O, De Walt D, et al. Parental literacy and
pediatric peritoneal dialysis outcomes. Abstract presented in
JASN 2007;18:299A.
[22] Davis TC, Wolf MS, Bass PF III, et al. Literacy and misun-
derstanding prescription drug labels. Ann Intern Med. 2006;
145:887–894.
[23] Grimes T, Delaney T, Duggan C, Kelly JG, Graham IM.
Survey of medication documentation at hospital discharge:
Implication for patient safety and continuity of care. Ir J Med
Sci. 2008;177:93–97.
[24] Ong SW, Fernades OA, Cesta A, Bajcar JM. Drug-related
problems on hospital admission: Relationship to medication
information transfer. Ann Pharmacother. 2006;40:408–413.
[25] National Kidney Foundation. K/DOQI clinical practice
guidelines for chronic kidney disease: Evaluation, classifica-
tion, and stratification. Am J Kidney Dis. 2002;39(Suppl. 1):
S1–S266.
